Clin2
NCT06666010Possibly a fitNot yet recruiting

Psilocybin-assisted therapy for stimulant use disorder

Stimulant Use Disorder

Part of Mental health clinical trials.

This trial tests whether a single dose of psilocybin (PEX010) combined with therapy can help people stop using methamphetamine or other stimulants. It focuses on safety and early signs of effectiveness.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
86 people
Ages
19 years to 65 years
Study type
Interventional

Who can take part

  • You are between 19 and 65 years old.
  • You have moderate to severe methamphetamine or other stimulant use disorder and want treatment.
  • You are not currently in another treatment program for substance use.
  • You have stable housing and a friend or family member who can stay with you after the dosing session.
  • You can stop using caffeine, cannabis, stimulants, and other drugs for a short time before the session.
  • You have no major medical conditions like heart disease, seizures, or uncontrolled high blood pressure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06323837Recruiting· Phase 2
Testing mirtazapine for methamphetamine use in people on opioid treatment

This trial tests whether the antidepressant mirtazapine can help reduce methamphetamine use in people who are already receiving medication for opioid use disorder. It aims to see if adding this medication improves outcomes for those struggling with both conditions.

Spokane, Washington
NCT06790576Recruiting· Phase 1
Optimizing TMS for stimulant use disorder

This test uses a safe, non-invasive brain stimulation method called TMS (transcranial magnetic stimulation) to see if it can help people with stimulant use disorder reduce their cravings and stay sober. You would need to be in an addiction treatment program and have been clean for at least 2 weeks to join.

Minneapolis, Minnesota
NCT06608459Not yet recruiting· Phase 2
Psilocybin-assisted therapy for opioid use disorder trial

This study tests whether psilocybin (a compound found in certain mushrooms), given with therapy, can help people with moderate to severe opioid use disorder reduce their opioid use. Participants must have stable housing and a support person to join.

NCT07774702Not yet recruiting· Phase 2
Psilocybin for methamphetamine use disorder

This trial tests whether a psychedelic drug called psilocybin can help people cut down or stop using methamphetamine. You'll take the drug in a supervised setting and get support to aim for full abstinence.

Birmingham, Alabama
NCT06899594Recruiting· Early Phase 1
Psilocybin for quitting methamphetamine

This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.

Shreveport, Louisiana
NCT06474026Recruiting
Focused Ultrasound for Stimulant Use Disorder

This trial tests a non-invasive brain treatment called focused ultrasound for people with stimulant use disorder (like methamphetamine or cocaine). It aims to help reduce cravings and improve recovery by gently stimulating a brain area involved in addiction.

Seoul, Seoul

Hear when a new Stimulant Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.